MUK Phase Ib trial to assess Reolysin + Imnovid / Revlimid combination to treat myeloma

Cancer charity Myeloma UK and biotechnolgy firm Oncolytics Biotech have commenced a Phase Ib MUK eleven trial of Reolysin (pelareorep) in combination with Imnovid (pomalidomide) or Revlimid (lenalidomide) to treat patients with relapsing myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news